UBS AM
MLYS icon

UBS AM’s Mineralys Therapeutics MLYS Stock Holding History

UBS AM’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
79,199
-338
-0.4% -$9.27K ﹤0.01% 2018
2026
Q1 		$2.15M Buy
79,537
+3,640
+5% +$107K ﹤0.01% 2011
2025
Q4 		$2.75M Buy
75,897
+16,855
+29% +$676K ﹤0.01% 1747
2025
Q3 		$2.24M Buy
59,042
+34,638
+142% +$749K ﹤0.01% 1703
2025
Q2 		$330K Buy
24,404
+16,604
+213% +$241K ﹤0.01% 2520
2025
Q1 		$124K Buy
+7,800
New +$89.7K ﹤0.01% 2592

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM's MLYS Position: Q2 2026 in Review

UBS AM reduced its Mineralys Therapeutics (MLYS) stake by 0.42% in Q2 2026, selling an estimated $9.27K and leaving 79,199 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2018.

UBS AM first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.75M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • UBS AM held 79,199 shares of Mineralys Therapeutics worth $2.14M as of Q2 2026.
  • UBS AM sold 338 Mineralys Therapeutics shares in Q2 2026, an estimated $9.27K.
  • Mineralys Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2018 holding.
  • UBS AM first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • UBS AM's Mineralys Therapeutics position peaked at $2.75M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.